A novel liquid-phase immunoassay is described which involves: competitive binding of the analyte and labelled antigen to specific antibodies; enzymic transformation of the free ligand to a more hydrophobic derivative; and separation of the antibody-bound and free ligand by partition of the reactants into an organic and aqueous phase. The principles of the method, described as ligand differentiation immunoassay, have been used in conjunction with a tritiated antigen to establish a continuous-flow system for the measurement of oestriol-16u-glucuronide in urine. Conventional autoanalyser (AAII) modules have been used, and the pump tubes and glass connections are standard accessories. The equipment is relatively inexpensive (£1500 + detector) and the reagents are readily available. Each sample takes 55 minutes to be processed, and 30 results are obtained per hour.
specific antibodies; (ii) the differential hydrolysis or conjugation of unbound ligand; and (iii) the partition of the reactants into an organic and aqueous phase. The entire procedure involves the sequential addition of four reagents in solution to the sample or standard: (i) labelled antigen, (ii) antibodies, (iii) enzyme, and (iv) organic solvent, and is particularly suitable for the measurement of steroid glucuronides and sulphates.
The technique of LIDIA for the measurement of oestriol-I 6 ex-glucuronide (E 3-1 6 ex-G) in diluted urine has been automated to investigate ovarian function over long periods of time. The results from related studies of folliculogenesis and steroid metabolism had suggested that the principal urinary metabolites of oestradiol might be used to predict and detect ovulation and thus locate the start and finish of the probable fertile period. Consequently, RIAs were developed to measure these metabolites in diluted urine. 14 -17 In addition, the measurement of E [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] ex-G has been used to assess fetal well-being.l" The continuous-flow LIDIA has been assessed in terms of sensitivity and precision. In addition, a comparison has been made between the results obtained from the measurement of E 3-16iX-G in daily samples of early morning urine (EMU) collected throughout a complete menstrual cycle by auto-analysis and those obtained by conventional RIA.
Equipment
The autoanalyser equipment used in the preliminary experiments was kindly loaned by Mr C Cook, of Chernlab Instruments Ltd, Hornchurch, Essex. The completed autoanalyser system (less detector) was purchased from Chemlab instruments and consisted of: a CS40 automatic sampler; a CPPI5 persitaltic pump; and a specially constructed manifold.
SAMPLER
The 40-cup sampler has a patented probe-washing mechanism which ensures that the samples are well separated. Sample and wash aspiration times can be selected by the use of independent controls.
PERISTALTIC PUMP AND PUMP TUBES
The Chemlab CPPI5 peristaltic pump consists of a constant-speed motor which drives stainless steel rollers and chains to give a flow rate of 0·015 ml to 3·9 ml of fluid per minute, depending on the internal diameter of the pump tubes. Two end blocks stretch the pump tubes across and between a spring-loaded pressure platten which brings the tubes into uniform contact with the rollers.
The pump tubes were as follows: (i) sample + label 295 intake: 0·32 rnl/min acid resistant tubing; (ii) antibody intake: 0·1 ml/rnin PVC tubing; (iii) enzyme intake: 0·1 rnl/min PVC tubing; (iv) air intake: O·32 ml/min PVC tubing; (v) scintillation fluid: 2·76 ml/min acid resistant tubing; (vi) wash probe feed: 1·40 ml/rnin PVC tubing; (vii) wash probe outlet (to waste): 3·90 ml/min PVC tubing.
MANIFOLD
The original arrangement of coils and tubes was constructed with standard autoanalyser parts linked together with acid resistant transmission tubing and sleeving, Every attempt was made to make the path length (from sample probe to detector) as short as possible. The incubation coils used in the preliminary experiments consisted of the 40 foot outer and inner coil contained in an autoanalyser oil bath. The heating facility, however, was not used, all incubations being performed at room temperature. Based upon the findings of the preliminary experiments, the manifold and flow system were redesigned. The flow diagram of the final version is shown in Figure 1 .
DETECTION SYSTEMS
Two detection systems have been used. In the preliminary experiments a fraction collecter (LKB Ultrarac; LKB Instruments Ltd, South Croydon, Surrey, UK) was connected to the outlet of the autoanalyser (method I). Fractions were collected for 15 seconds into polypropylene beta-vials (Hughes and Hughes Ltd, Romford, Essex, UK). The vials were stoppered and the radioactivity was determined in a liquid scintillation counter. Subsequently, a Flo-one radioactive flow detector (Radiomatic Instruments and Chemical Co Inc, Addison, Illinois, USA) kindly loaned by LKB Instruments Ltd, was connected to the outlet of the autoanalyser (method 2). The detector, essentially a liquid scintillation counter equipped with a flow-cell, was originally devised to monitor radioactive eluates from high performance liquid chromatography equipment. A flat bed recorder was connected to the detector to monitor the output. The principle of the assay is as follows:
where (E a·-16ot-G) is a tritiated antigen and (Ab) is a limited concentration of antibodies; (ii) Differential antigen hydrolysis
where the bound ligand is protected against hydrolysis; and (iii) Solvent partition
where the scintillation fluid is 5 g PPO/litre toluene: ethanol; 99:1 (v/v) and the bound ligand remains hydrophilic (ie, E a·-16ot-G), it is not taken up into the organic phase and does not interfere with the scintillation process.
ASSAY PROCEDURE
Samples of EMU were collected from a healthy woman throughout the menstrual cycle. Before assay 100 !Jol of urine was diluted to 1 ml by the addition of 900 !Jol assay buffer containing 6,7-aH-E a-16ot-G (5000 cpm/l00 !Jo1). Alternatively, standard solutions of E a-16 ot-G (range 0--400 ng/ml) were diluted 1: 10 (v/v) with assay buffer containing 6,7-aH-E a,·16ot-G (5000 cpm/100 !Jo1). The optimum sample-to-wash time ratio was determined by the preparation of replicate calibration curves under defined conditions. The' enzyme concentration was 4 mg/rnl assay buffer, and the antibody concentration was 1:5000 (v/v) of the IgG fraction diluted in assay buffer. The standard solutions of E a-16et-G (range 0-400 ng/rnl) were diluted 1:10 (v/v) with assay buffer containing 6,7-aH-E a-16et-G (5000 cpm/loo fLl). 1 ml of each diluted standard was transferred into the appropriate sample cups. The autoanalyser was connected to a fraction collecter and l5-second fractions were collected into beta-vials and the radioactivity was determined.
In the first experiment, each cup was sampled by the probe for 60 seconds. The wash time between each sample varied from 30 seconds for the first calibration curve to 120 seconds for the last. The results are shown in Figure 2 . A second series of calibration curves were constructed with a sampling time of 30 seconds. The results are shown in Figure 3 . It was concluded that the optimum sampling time was 30 seconds with a wash time of 90 seconds. This gave an overall rate of 30 samples per hour.
ANTIBODY DILUTION
The optimum antibody dilution was determined by producing calibration curves with increasing dilutions of the antiserum in assay buffer (range 1:1000 to 1:16000 v/v). The results are shown in Figure 4 . It was concluded that the optimum dilution of antibody was 1:3000 (vIv). 0·1 % sodium azide, 9 % sodium chloride; pH 7·5) was used. The major problem encountered, however, was significant carry-over caused by the serious adsorption of the labelled steroid and other constituents of the assay to the walls of the pump tubes and glass coils, exacerbated by the long path length. This problem was overcome by the use of two buffers: (1) an assay buffer which consisted of the O·lM phosphate buffer with the addition of Tween 20 (0·25 %); and (2) a wash buffer which consisted of the 0·1M phosphate buffer with the addition of Tween 20 (0·5 %) and ethanol (5 %). Buffer 1 was used in the preparation of all reagents (ie, labelled steroid, dilution of standards and samples, antibody and enzyme solutions) and buffer 2 was aspirated into the system by the probe between each sample to remove any residual sample from the system before the aspiration of the next sample.
ENZYME CONCENTRATION
The optimum enzyme dilution was determined by producing calibration curves with increasing con- Calibration curves were obtained with the Flo-one detector and flat bed recorder and an example is shown in Figure 6 . The least amount of E a-16rz-G that could be detected based upon the precision of zero dose (mean + 2SD) was determined by replicate analysis, and the result was 3·1 ng/rnl, corresponding to 6·68 nmol/I urine. PRECISION Replicate analyses were performed on three urine pools as a measure of intra-assay variation, and the results are shown in Table I. centrations of~-glucuronidase in assay buffer (range 0·5--4 mg/rnl), The results are shown in Figure 5 . It was concluded that the optimum concentration of enzyme was 4 mg/ml. In order to assess the potential clinical usefulness of the method, the concentration of E a-16oc-G was measured in daily samples of EMU collected throughout one menstrual cycle by automated LIDIA and a well-evaluated RIA using Dextran-coated charcoal to separate the antibody bound and free fractions. 'The results are shown in Figure 7 . Ligand differentiation immunoassay is a novel approach to the development of immunological techniques. The liquid/liquid partition has eliminated the need for centrifugation as in conventional liquid-phase RIA and provides a simpler alternative to the washing procedures required to reduce non-specific binding associated with solidphase techniques. The reagents are easy to prepare and may be supplied as a kit. Moreover, since the two-phase partition obviates the need for the physical removal of either the antibody-bound or free fraction, all the reactions can take place within the one assay tube. To date, procedures have been devised and evaluated for the measurement of 13 compounds of biomedical interest which include steroids.P? steroid glucuronides and sulphates,28-30 thyroid hormones, prostanoids, and drugs.P! The method is particularly, but not exclusively, suitable for the measurement of water-soluble excretion products and is part of a trend towards the development and application of non-invasive techniques to investigate ovarian function and to detect earlỹ ;., 160 w Continuous-flow methodology has the following advantages: (i) the only variable consumable associated with the sample is the cup--the other components (eg, pump tubes) are fixed and replaced after a preset number of hours of use; (ii) each sample or standard goes through the same pathway under identical conditions; (iii) the reagent volumes are small and costs can be kept to a minimum; (iv) the pregnancy in humans and domestic animals (eg, the measurement of oestrone-3-sulphate in milk). In addition, there is good suggestive evidence that the method may be applied to the measurement of protein hormones, provided suitably labelled derivatives can be prepared.v The present report has shown that the principles of LIDIA may be used to establish a continuous-flow, radioimmunoassay system for the measurement of oestriol-16ot.-glucuronide in urine. Conventional autoanalyser (AAII) modules have been used, and the pump tubes and glass connections are standard accessories. The equipment is relatively inexpensive (£1500 + detector) and the reagents are readily available. Each sample takes 55 minutes to be processed and 30 results are obtained per hour. An overall increase in this relatively slow sample rate could be achieved by the incorporation of shorter incubation coils with or without temperature control. This would significantly reduce the path length and the necessary wash time interval.
In addition, the system may be modified for the measurement of fluorescence or chemiluminescence by the use of alternative labels and detection systems. To date, several non-isotopic immunoassays have been reported which obviate the need to separate antibody-bound and free fractions.P In nearly every example background interference has been a major problem, reducing assay specificity and sensitivity. It is envisaged that non-isotopic LIDIA will combine the advantages of the homogeneous assay while being unaffected by the constraints of biological interference for the following reasons: the interfering factors are preferentially retained in the aqueous phase ;33 and the fluorescent or chemiluminescent signal may be enhanced in the hydrophobic phase.P! Both of these factors are complementary and may lead to an increase in the signal-to-noise ratio, thus increasing sensitivity and specificity. It is envisaged that a hydrophobic fluorescent or chemiluminscent conjugate will be protected against cleavage when bound to specific antibodies. The antibody-free fraction is cleaved enzymically, or with mild chemical treatment, to produce hydrophilic fragments. The bound fraction is stripped from the antibody by the addition of an appropriate organic solvent and the label is measured in the organic phase. The method is particularly suited to the use of fluorescent labelled derivatives but may also be appropriate with chemiluminescent labels such as acridines, dioxetanes or peroxyoxalates which can be oxidised in nonaqueous systems with the emission of light.35
